The emerging class of GLP-1 receptor and GIP dual medications, such as tirzepatide, semaglutide, and the newly introduced retatrutide, represent groundbreaking progress in metabolic management . Although https://semaglutide742507.thunkblog.com/940651/semaglutide-the-thorough-look